The Behavioral Economist
Behavioral finance, growth, small-cap, fund holdings

Stellar Biotechnologies: Innovation, Experience, And Upside

The biotechnology sector, as an investment vehicle, is a high risk endeavor. Whether a company operates in the pre-clinical phases, or is an active member of the "Big Pharma Fraternity", the exposure to potential project failure is considerable. Admittedly, the superior resources of larger and more established entities provide greater downside protection. However, regardless of an entities market capitalization and financial strength, all biotechnology companies are subject to rigorous oversight, laborious processes, and FDA evaluation. Thus, in context, all biotechnology enterprises are faced with the same arduous journey.

One such company, currently devoted to making this often treacherous expedition, is Stellar Biotechnologies (OTCQB:SBOTF). Stellar is, arguably, the world leader in both research, and sustainable development of, ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details